Targeted therapies, including EGFR-tyrosine kinase inhibitors (EGFR-TKIs), have been approved in Brazil and used in front-line settings in NSCLC patients whose tumors harbor EGFR activating mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.